Atrium Therapeutics, Inc. Common Stock (RNA) — Free Cash Flow Generation Index

Latest as of December 2023: 0.95x

Atrium Therapeutics, Inc. Common Stock (RNA) has a Free Cash Flow Generation Index of 0.95x as of December 2023. Free cash flow of $15.64 Million represents 1% of operating cash flow ($16.50 Million). See Atrium Therapeutics, Inc. Common Stock working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

FCF Generation Index

0.95x
Free Cash Flow / Operating CF

Free Cash Flow

$15.64 Million
USD

Operating Cash Flow

$16.50 Million
USD

Capital Expenditures

$863.00K
USD

Atrium Therapeutics, Inc. Common Stock Free Cash Flow Generation Index (2019–2019)

Historical FCF Generation Index trend for Atrium Therapeutics, Inc. Common Stock across 1 annual periods. Explore cash flow to debt ratio of Atrium Therapeutics, Inc. Common Stock to assess how comfortably operating cash covers total debt obligations.

Annual Free Cash Flow Generation for Atrium Therapeutics, Inc. Common Stock (2019–2019)

Year-by-year Free Cash Flow Generation Index for Atrium Therapeutics, Inc. Common Stock. For the full company profile including market capitalisation, see RNA company net worth.

Year FCG Index Free Cash Flow (USD) Operating CF Capital Expenditures YoY Change
2019 0.91x $2.25 Million $2.49 Million $235.00K —
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).